<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-91563</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Vaccines and chemo-prophylaxis in rhemautoid arthritis: is a vaccine calendar necessary?</dc:title>
<dc:description xml:lang="en">Patients with rheumatoid arthritis (RA) are at increased risk of infection compared to healthy individuals. The increased risk may be associated with the underlying disease, comorbidities and immunosuppressive therapy required to control RA activity. In several recent studies, influenza, pneumococcal and hepatitis B vaccines administered to RA patients were reported to be safe and serologically effective. However, several lines of evidence suggest a possible aberrant immunologic response following vaccination due to the compromised immunity of these patients. Therefore, vaccination of RA patients prior to immunosuppressive treatment may serve as an alternative prophylactic approach and should be considered for future investigation. Besides, prophylactic health measures should be taken to avoid latent chronic infections as tuberculosis and hepatitis B, during therapy with biological agents(AU)</dc:description>
<dc:creator>Navarro Sarabia, Federico</dc:creator>
<dc:creator>Garrido López, Belén Carmen</dc:creator>
<dc:creator>Navarro Compain, María Victoria</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los pacientes con artritis reumatoide (AR) tienen mayor riesgo de presentar infecciones respecto a la población sana. Éste principalmente se debe a la enfermedad en sí, a la comorbilidad y al tratamiento inmunosupresor. La evidencia clínica demuestra que la administración de las vacunas frente al neumococo y los virus influenza y hepatitis B en pacientes con AR no empeora la actividad de la enfermedad, y que éstas son eficaces, aunque parece que la respuesta inmunitaria se ve reducida por la propia enfermedad y el tratamiento con FAME y biológicos. Por ello, es aconsejable vacunar a los pacientes al diagnóstico, antes de iniciar el tratamiento con inmunosupresores. También existen y se deben tomar medidas profilácticas para evitar la reactivación de infecciones latentes crónicas como la tuberculosis y la hepatitis B durante el tratamiento con biológicos(AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);7(6): 412-416, nov.-dic.2011. ilus</dc:source>
<dc:identifier>ibc-91563</dc:identifier>
<dc:title xml:lang="es">Vacunas y quimioprofilaxis en artritis reumatoide: ¿podría plantearse un calendario de vacunación?</dc:title>
<dc:subject>^d14778^s22012</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d1178^s22080</dc:subject>
<dc:subject>^d6721^s22038</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6721^s22012</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d32808^s22074</dc:subject>
<dc:subject>^d6664^s22012</dc:subject>
<dc:subject>^d32808^s22045</dc:subject>
<dc:subject>^d7344^s22073</dc:subject>
<dc:subject>^d1178^s22038</dc:subject>
<dc:subject>^d32808^s22066</dc:subject>
<dc:subject>^d32808^s22018</dc:subject>
<dc:subject>^d6664^s22016</dc:subject>
<dc:subject>^d29592^s22045</dc:subject>
<dc:subject>^d29592^s22066</dc:subject>
<dc:subject>^d14778^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201112</dc:date>
</metadata>
</record>
</ibecs-document>
